Gamal F. Ellatef-Abd
Giza, GZ, Egypt
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Evaluation of the anti-hyperglycemic, anti-hyperlipidemic, cardioprotective and anti-inflammatory effects of a xanthine-based dipeptidyl peptidase-4 inhibitor and diosmin in NA/STZ-induced diabetic rats.
Journal: Archives of physiology and biochemistry
Published: January 08, 2026
An Overview of Targeting Some Cancer Hallmarks with Plant Polyphenols: A Step Toward Precision.
Journal: Sub-cellular biochemistry
Published: January 01, 2026
Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery.
Journal: European journal of medicinal chemistry
Published: June 27, 2025
Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present).
Journal: Bioorganic & medicinal chemistry
Published: February 24, 2025
Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.
Journal: Toxicology reports
Published: November 12, 2024
In silico analysis and comprehensive review of circular-RNA regulatory roles in breast diseases; a step-toward non-coding RNA precision.
Journal: Pathology, research and practice
Published: September 02, 2024
Corrigendum to 'Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein' [Pharmacol. Res. 175 (2022) 105975].
Journal: Pharmacological research
Published: March 03, 2023
Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Journal: Pharmacological research
Published: August 18, 2021
Correction to "Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance".
Journal: ACS medicinal chemistry letters
Published: March 21, 2019
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.
Journal: ACS medicinal chemistry letters
Published: January 11, 2017
Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: September 20, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026